DIN 02559676 — ALYFTREK 20 MG; 4 MG; 50 MG
ALYFTREK is a tablet of Deutivacaftor / Tezacaftor / Vanzacaftor marketed by VERTEX PHARMACEUTICALS (CANADA) INCORPORATED. The full Deutivacaftor / Tezacaftor / Vanzacaftor monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02559676
- Brand name
- ALYFTREK
- Active ingredient
- Deutivacaftor / Tezacaftor / Vanzacaftor
- Strength
- 20 MG; 4 MG; 50 MG
- Dosage form
- TABLET
- Route
- ORAL
- Manufacturer
- VERTEX PHARMACEUTICALS (CANADA) INCORPORATED
- Health Canada status
- MARKETED
- Drug class
- Cystic fibrosis transmembrane conductance regulator (CFTR) corrector and potentiator combination
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Deutivacaftor / Tezacaftor / Vanzacaftor products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02559684 | ALYFTREK | 50 MG; 10 MG; 125 MG | TABLET | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED | MARKETED |